This clinical trial is focused on studying the effects of a medication called ticagrelor, which is used in patients who have experienced a myocardial infarction, commonly known as a heart attack. The study is specifically looking at patients who have undergone a procedure called coronary stenting, where a small tube is placed in the heart’s blood vessels to keep them open. The purpose of the study is to evaluate the initial safety of using ticagrelor alone, without other medications, after this procedure.

Participants in the study will take Brilique 90 mg film-coated tablets, which contain ticagrelor, for a period of time. The study will monitor the participants for any serious heart-related events, such as cardiac death, another heart attack, or issues with the stent, within the first three months. Additionally, the study will observe the occurrence of bleeding events and other health outcomes over a period of up to 12 months.

The study aims to gather information on how safe it is to use ticagrelor as a single treatment after a heart attack and stenting. This will help doctors understand if this approach can be a reliable option for patients in the future. Participants will be closely monitored throughout the study to ensure their safety and to collect valuable data on the effects of the medication.